10x Genomics (10x Genomics) Forward Dividend Yield % : 0.00% (As of Apr. 26, 2024)

View and export this data going back to 2019. Start your Free Trial

What is 10x Genomics Forward Dividend Yield %?

As of today (2024-04-26), the Forward Annual Dividend Yield of 10x Genomics is 0.00%.

As of today (2024-04-26), the Trailing Annual Dividend Yield of 10x Genomics is 0.00%.

TXG's Forward Dividend Yield % is not ranked ^*
in the Healthcare Providers & Services industry.
Industry Median: 2.28
* Ranked among companies with meaningful Forward Dividend Yield % only.

10x Genomics's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of 10x Genomics's Forward Dividend Yield %

For the Health Information Services subindustry, 10x Genomics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

10x Genomics's Forward Dividend Yield % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where 10x Genomics's Forward Dividend Yield % falls into.

10x Genomics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

10x Genomics (NAS:TXG) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

10x Genomics Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of 10x Genomics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

10x Genomics (10x Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » 10x Genomics Inc (NAS:TXG) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

1KJ:Germany

Address

6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588

Website

https://www.10xgenomics.com

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Executives

Serge Saxonov	director, 10 percent owner, officer: Chief Executive Officer	10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
James Wilbur	officer: Chief Commercial Officer	C/O 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588-3260
Benjamin J. Hindson	director, officer: See Remarks	10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Justin J. Mcanear	officer: Chief Financial Officer	10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
John R Stuelpnagel	director	10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Mathai Mammen	director	THERAVANCE,INC., 901 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Bradford Crutchfield	officer: Chief Commercial Officer	6230 STONERIDGE MALL ROAD, PLEASANTON CA 94547
Sridhar Kosaraju	director	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Bryan E Roberts	director	C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025
Venrock Management Vi, Llc	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Associates Vi, L.p.	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Vi, L.p.	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Management Vi, Llc	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Foresite Capital Fund I, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Paladin Capital Management, Llc	10 percent owner	2020 K STREET, NW, SUITE 620, WASHINGTON DC 20006